In terms of twelve month growth in earnings before interest and taxes, Chembio Diagnostics Inc is reporting a growth rate of 50.56%; that's higher than 81.55% of US stocks.
The volatility of Chembio Diagnostics Inc's share price is greater than that of 91.67% US stocks with at least 200 days of trading history.
Chembio Diagnostics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -22.15%, greater than the shareholder yield of just 11.76% of stocks in our set.
Stocks that are quantitatively similar to CEMI, based on their financial statements, market capitalization, and price volatility, are VJET, SANW, AMOT, MDRX, and HTGM.
Chembio Diagnostics, Inc., together with its wholly-owned subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care (POC) diagnostic tests that detect infectious diseases. The company was founded in 1985 and is based in Medford, New York.
Enters Exclusive U.K. and Ireland Distribution Agreement with Luas DiagnosticsHAUPPAUGE, N.Y., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the CE mark for the DPP SARS-CoV-2 Antigen and IgM/IgG test systems, providing regulatory approval to register and market both test systems in the European Union and other geographies that accept the CE mark. The Company also announced that it has entered into a distribution agreement with Luas Diagnostics, which will commence system sales immediately while serving as the exclusive commercial partner for all of Chembio’s products in the United Kingdom and Ireland. “Having the CE mark for both COVID-19 test systems is indicative ...
HAUPPAUGE, N.Y., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the appointment of David Acheson, M.D. to the Company’s Board of Directors. “We are pleased to welcome David to our Board of Directors. He adds directly applicable expertise in public health and infectious disease management to our leadership team, and we are confident his perspective will contribute meaningfully to our long-term value creation strategy,” said Katherine L. Davis, Chair of Chembio's Board of Directors. “We look forward to his leadership and insights as we enter the next phase of growth for Chembio.”Dr. David Acheson has served as the President and Chief Executive Officer of The Acheson Gro...